If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
174
results.
Updated on
21/09/2026 [08:30:00]
Results 100 to 125 of 174
Absstract of: CN224573044U
The utility model relates to the technical field of medical instruments, and discloses a disposable safe insulin pen needle which is characterized in that a needle point protective sleeve is arranged in a shell, a locking ring is arranged in the needle point protective sleeve, a spring is arranged between the locking ring and a needle seat, and a first limiting groove and a second limiting groove are formed in the inner wall of the shell; a blocking edge is arranged at the groove head end of the second limiting groove, a first protruding block sliding in the first limiting groove is arranged on the outer wall of the needle point protection sleeve, a guide face is arranged on the end edge of the tail end of the needle point protection sleeve, and the guide face extends from the axial side of the first protruding block to the circumferential side of the first protruding block. The outer wall of the locking ring is provided with a second protruding block which slides in the first limiting groove along the guiding face. According to the disposable safe insulin pen needle, the telescopic needle point protection sleeve is designed, the stroke of the needle point protection sleeve is limited, the needle point protection sleeve cannot retract again after covering the needle point, and the purposes of disposable use and needling prevention are achieved.
Absstract of: CN224573047U
The utility model provides a needle anti-stabbing device for an insulin pen, which relates to the technical field of needle anti-stabbing, and comprises a shell, a support column is fixedly mounted on the shell, a rotating shell is mounted between the shell and the support column in a rotating manner, the needle anti-stabbing device further comprises a blocking mechanism and a clamping mechanism, the blocking mechanism is arranged on the shell, and the clamping mechanism is arranged on the rotating shell. A plurality of sets of loading mechanisms are movably installed on the rotating shell, and clamping mechanisms are arranged on the loading mechanisms. The sterile needle head body is protected through mutual cooperation of the inner shell and the cover body, the button drives the rubber clamping piece to extrude the needle head body by opening the cover body and pressing the button, the insulin pen thread and the needle head body can be fixed conveniently, and after use, the needle head body is prevented from being damaged. The needle head body is moved between the two rubber clamping pieces by moving the insulin pen, and the needle head body is detached from the insulin pen by pressing the button, so that the needle head body does not need to be touched in the whole use process, and the puncture prevention effect is improved.
Absstract of: CN122478931A
The invention belongs to the field of biological medicines, and particularly relates to application of SAFit2 in preparation of a medicament for promoting wound healing of diabetic feet. The small molecule compound SAFit2 can be used for preparing a medicine for promoting healing of a diabetic wound surface, and the medicine for promoting healing of the diabetic wound surface comprises a medicine for promoting healing of a refractory wound surface of a diabetic patient. The research shows that the SAFit2 can remarkably promote wound healing of diabetic model mice and reduce apoptosis of skin cells in a high-glucose environment, so that the effect of promoting wound repair is achieved. The invention provides a new direction and idea for the repair of the refractory wound surface, and provides a new drug development direction for the repair of the refractory wound surface.
Absstract of: CN224573049U
The utility model relates to the field of medical instruments, in particular to a multifunctional insulin injection site alternation plate. The utility model provides a multifunctional insulin injection site alternation plate which can mark an injection site while injecting insulin, is convenient for next injection, prevents repeated injection at the same position, reduces damage to skin and adipose tissue, improves the treatment effect, and is safe and convenient to use. A multifunctional insulin injection site alternation plate comprises a bottom plate, mucilage glue blocks and the like, and the mucilage glue blocks are connected to the left portion and the right portion of the bottom plate. The insulin needle is taken down, the insulin needle penetrates through the needle inlet hole, then the movable block is pressed to move, the marking block moves to make contact with the affected skin for marking, the insulin needle pierces the skin of a patient for injection, and therefore an injection part can be marked while insulin is injected, and next injection is facilitated; repeated injection at the same position is prevented, skin and adipose tissue damage is reduced, the treatment effect is improved, and use is safe and convenient.
Absstract of: CN122478853A
The invention belongs to the technical field of biological medicine, and particularly relates to a stem cell exosome and protective agent composition and application thereof. The invention discloses a stem cell exosome and protective agent composition. The composition is prepared from the following raw materials in parts by weight: 1.2 to 2.5 parts of hydroxytyrosol glucoside, 1 to 2 parts of potassium azelaic diglycinate, 20 to 30 parts of poloxamer 407, 1 to 4 parts of sodium hyaluronate and 30 to 45 parts of water. The composition further comprises mesenchymal stem cell exosomes, and the concentration of the mesenchymal stem cell exosomes in the composition is (0.8-1.5) * 10 < 10 >/mL. The test result shows that the composition of the stem cell exosome and the protective agent can maintain the freeze-drying stability and the structural integrity of the exosome through the cooperation of the hydroxytyrosol glucoside and the potassium azelaic diglycinate; the wound healing is obviously promoted, the oxidation resistance is enhanced, the inflammation microenvironment is regulated to be converted into anti-inflammation, and the application prospect is wide.
Absstract of: CN122478489A
The invention discloses a multi-parameter non-invasive health monitoring method based on an FPGA-MCU heterogeneous architecture. The multi-parameter non-invasive health monitoring method comprises the following steps: S1, multi-frequency signal excitation and data acquisition; s2, FPGA parallel real-time impedance calculation, data transmission and fusion modeling are carried out; s3, performing fusion prediction on multiple physiological parameters; and S4, carrying out risk early warning and health assessment. According to the method, the excitation frequency is expanded to 2 MHz, the physical characteristic that the skin cuticle capacitance effect tends to zero under the high-frequency condition is utilized, a deep human tissue impedance equivalent model is established in combination with high-frequency-band least square linear fitting, and systematic elimination of skin surface interference is achieved; the extracted deep tissue equivalent pure resistance parameters are highly related to deep physiological indexes such as blood volume and tissue fluid content, the fundamental limitation that only surface impedance can be obtained through an existing bioelectrical impedance technology is remarkably broken through, and meanwhile physiological parameters such as blood glucose and blood pressure can be more effectively detected by means of a deep human body impedance spectrum.
Absstract of: NZ800857A
Described herein are fixed doses and dosing regimens for long-acting insulin receptor agonists suitable for once-weekly dosing, such as weekly basal insulin-Fc (BIF).
Absstract of: CN122479244A
The invention belongs to the technical field of medical instruments, and particularly relates to an automatic insulin injection device for monitoring blood sugar and blood potassium and a control method. The concentration of glucose and potassium ions in tissue fluid is synchronously obtained through a flexible dual-mode sensing patch; correcting the potassium ion concentration in combination with data such as body temperature and heart rate variability into estimated serum potassium concentration by using a lightweight neural network model; only when the blood sugar is higher than a threshold value and the blood potassium is in a safety interval (3.5-5.0 mmol/L), automatic injection of insulin is allowed; if the blood potassium is too high (gt, 5.5 mmol/L), injection is forbidden and an alarm is given, if the blood potassium is too low (lt, 3.0 mmol/L), the single dose is limited, and the device is integrated on an arc-shaped waist-wearing type shell, comprises a miniature insulin pump, a controller and a hose, and has the equipment state self-checking and multi-channel alarm functions. The safety of closed-loop insulin treatment is remarkably improved, and the method is particularly suitable for high-risk people with renal insufficiency and the like.
Absstract of: CN122494216A
The invention aims to provide an advanced fusion scheme capable of surpassing surface vision and integrating multispectral data capable of reflecting deep perfusion and thermal imaging data capable of reflecting inflammation so as to realize accurate quantitative evaluation of early deep infection of a wound and tissue activity. The first aspect of the invention is to disclose a wound deep physiological status intelligent identification method based on multispectral and thermal imaging fusion. The second aspect of the invention is to disclose a wound deep physiological status intelligent identification system based on multispectral and thermal imaging fusion, which is characterized by comprising a heterogeneous data acquisition front end; an edge deep learning processor; and a visual intervention terminal. According to the high-precision and non-contact intelligent identification method and system for the deep physiological status of the wound, quantitative evaluation of early deep infection, ischemia and tissue activity distribution of the chronic wound is realized by fusing multispectral and thermal imaging data; and non-invasive and high-precision intelligent identification and risk assessment can be carried out on the early deep physiological status of chronic wounds (such as diabetic foot ulcer or pressure sores).
Absstract of: US20260215686A1
0000 Various embodiments of systems, devices and methods for improving the accuracy of an analyte sensor and for detecting sensor fault conditions are disclosed. According to some embodiments, these systems, devices, and methods can utilize a first data collected by a glucose sensor and a second data collected by a secondary sensing element. In some embodiments, the secondary sensing element can be one of a lactate sensing element, a ketone sensing element, or a heart rate monitor, among others.
Absstract of: WO2026160421A1
The present disclosure provides cells that exhibit competitiveness with respect to cancer cells without being starved and exhausted even in a glucose depleted environment. More specifically, the present disclosure provides cells that are effective in metabolic (for example, low glucose, high lactic acid, and high fatty acid environments) and immunological tumor environments (chemokine profiles that induce immunosuppressive immune cells, expression of checkpoint molecules, and inhibitory cell infiltration that negatively regulates antitumor immune responses, the inhibitory cells being typified by inhibitory cytokines and Treg cells) in which infiltration by normal T-cells or conventional genetically modified cells are inhibited, and in which, in addition, even if infiltration occurs, said cells cannot exhibit long-term effector functions due to starvation and exhaustion. The present disclosure also provides T-cells having an effector function, wherein the T-cells are modified so as to express Foxp3 (including mutants and partial deletions), and/or have an enhanced expression of Foxp3.
Absstract of: US20260216060A1
0000 The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with needle height dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.
Absstract of: WO2026157245A1
Disclosed in the present application are a method for evaluating blood glucose, a user interface, and a related apparatus. The method comprises: obtaining a PPG signal of a user in a time period; displaying the acquisition progress of the PPG signal in the process of obtaining the PPG signal; and then determining a blood glucose result of the user on the basis of the PPG signal, and displaying the blood glucose result. When the acquisition progress of the PPG signal is determined, the method can divide the PPG signal into PPG signal intervals in a plurality of windows by using a specified duration as a window size, and determine a ratio of the number of valid PPG signal intervals in the plurality of PPG signal intervals to a preset number as the acquisition progress of the PPG signal. It can be seen that the method determines the acquisition progress of the PPG signal according to the number of valid PPG signal intervals divided from the PPG signal, such that the acquisition progress of the PPG signal better aligns with the user's actual perception of the signal acquisition progress during the course of PPG signal acquisition.
Absstract of: US20260216283A1
0000 Chronic wounds are characterized by a persistent, hyper-inflammatory environment that prevents progression to regenerative wound closure. Such chronic wounds are especially common in diabetic patients, often requiring distal limb amputation, but occur in non-diabetic, elderly patients as well. Induced expression of HoxA3, a member of the Homeobox family of body patterning and master regulatory transcription factors, has been shown to accelerate wound closure in diabetic mice when applied topically as a plasmid encased in a hydrogel. We now provide independent replication of those foundational in vivo diabetic wound closure studies and expand upon them with minimal dose threshold estimation. Furthermore, we observed similarities in natural wound healing velocity between aged non-diabetic mice and young diabetic mice, which provided motivation to test topical HoxA3 plasmid in aged non-diabetic mice, where we again observed accelerated wound healing. We did not observe any gross adverse effects macroscopically or via local histology in these short studies. Whether as a plasmid or future alternative modality, topical HoxA3 is an attractive translational candidate for chronic wounds.
Absstract of: US20260215703A1
0000 Provided is a sensor applicator assembly for a blood glucose monitoring, comprising an applicator, and a body attachment unit disposed inside the applicator and comprising a housing including an upper frame and a lower frame. The lower frame comprises a recess portion formed throughout an entire section along a perimeter direction.
Absstract of: US20260219259A1
A method to rapidly and inexpensively quantify human insulin secreted from human cells. This method for quantifying insulin secretion capacity in a human cell involves culturing a recombinant cell and measuring an amount of a secreted fused C-peptide. The recombinant cell is prepared by replacing an insulin gene in the genome of a human cultured cell line with a gene which expresses a fused C-peptide having a detectable tag peptide inserted in a C-peptide chain in a human proinsulin molecule.
Absstract of: US20260216422A1
A user-wearable patch pump system for delivery of insulin or other medicament can include a patch pump having a reusable drive unit and a replaceable and refillable cartridge. The cartridge can selectively attach to and be detached from the drive unit. The cartridge can initially be inserted onto the drive unit in a first orientation at an angle to the drive unit and then be rotated to align the cartridge with the drive unit and lock the cartridge in place on the drive unit to form the patch pump.
Absstract of: US20260215741A1
Methods, devices, systems, and kits are provided that buffer the time spaced glucose signals in a memory, and when a request for real time glucose level information is detected, transmit the buffered glucose signals and real time monitored glucose level information to a remotely located device, process a subset of the received glucose signals to identify a predetermined number of consecutive glucose data points indicating an adverse condition such as an impending hypoglycemic condition, confirm the adverse condition based on comparison of the predetermined number of consecutive glucose data points to a stored glucose data profile associated with the adverse condition, where confirming the adverse condition includes generating a notification signal when the impending hypoglycemic condition is confirmed, and activate a radio frequency (RF) communication module to wirelessly transmit the generated notification signal to the remotely located device only when the notification signal is generated.
Absstract of: US20260215704A1
A medical device includes a medical tool such as an inserter for a continuous glucose monitor. Typically a housing of the medical tool has an indicator area with an indicator field that irreversibly changes its appearance at a predetermined environmental parameter condition. In exemplary embodiments, the predetermined environmental parameter condition can be a predetermined humidity, a change in a predetermined humidity condition, a predetermined temperature or a predetermined temperature change. A controller is connected to the medical tool and is configured to determine the appearance of the indicator field at the time of use of the medical tool and is also configured to control the function of the medical tool based upon the determined appearance of the indicator field.
Absstract of: WO2026156536A1
The present application discloses a video product for inducing a cognitive impairment behavior, and a storage medium. The video product comprises a plurality of video units, each video unit comprises a plurality of video clips, and each video clip displays a target element, a prompt element and/or an interference element. In the present application, by means of different elements in the video clips, a subject is induced to make behavioral responses, thereby measuring multiple types of cognitive abilities of the subject including visuospatial ability, memory ability, language ability, calculation ability, complex attention ability, smooth pursuit ability, execution ability, social cognition ability, emotional response ability, incongruity detection ability, and narrow vision ability, thus achieving screening, diagnosis, treatment, and efficacy evaluation of cognitive impairment caused by Alzheimer's disease, Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, vascular dementia, diabetes, and the like. By using the video product of the present invention, the processes of the described screening, diagnosis, treatment, and efficacy evaluation are more objective, and the results have higher reliability and consistency.
Absstract of: WO2026157189A1
The present invention relates to a cartilage organoid constructed on the basis of a DNA-fibroin hybrid hydrogel sustained-release system, a method for preparing same, and use thereof. The DNA-fibroin hybrid hydrogel sustained-release system is a hydrogel system obtained after a pre-mixed solution of the DNA-fibroin hybrid hydrogel sustained-release system is printed by means of a digital light processing system, wherein the pre-mixed solution of the DNA-fibroin hybrid hydrogel sustained-release system comprises DNA, fibroin, an acrylated RGD peptide, an acrylated polyethylene glycol NHS ester, glucosamine, TD-198946, and lithium 2,4,6-trimethylbenzoylphosphate. Compared to the prior art, the glucosamine and TD-198946 introduced into the DNA-fibroin hybrid hydrogel sustained-release system of the present invention can significantly improve the efficiency of promoting the chondrogenic differentiation of bone marrow mesenchymal stem cells. The present invention can be transplanted as a cartilage graft to a cartilage defect site to promote cartilage regeneration and repair.
Absstract of: AU2026205438A1
STEM CELL DERIVED ISLET DIFFERENTIATION Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells. STEM CELL DERIVED ISLET DIFFERENTIATION ul u l
Absstract of: WO2026157932A1
Provided is a deuterium-labeled probe for diagnosing and monitoring AD using a magnetic resonance deuterium imaging application technology. The present invention provides use of a deuterium-labeled molecular probe or a composition comprising a deuterium-labeled molecular probe in the preparation of a kit or system, wherein the kit or system is used for accurately diagnosing Alzheimer's disease or dynamically monitoring progression of Alzheimer's disease in a subject, the deuterium-labeled molecular probe is selected from deuterium-labeled glucose, a deuterium-labeled acetate, or a deuterium-labeled amino acid, and the Alzheimer's disease is early-stage, intermediate-stage, or late-stage Alzheimer's disease. The present invention achieves early and accurate detection of Alzheimer's disease.
Absstract of: CN121843651A
A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure a ketone level in a patient's bodily fluid. The application is configured to display at least one of (1) a current ketone level, and an indicator of a current ketone trend, (2) a ketone trend graph, and (3) a total amount of time for which the ketone level is above at least one predetermined threshold level. The application is further configured to determine whether the current ketone level is above the at least one predetermined threshold level, and output an alert in response to determining that the current ketone level is above the at least one predetermined threshold level, where the alert is periodically output when the current ketone level is above the at least one predetermined threshold level.
Nº publicación: ES3075244T3 29/07/2026
Applicant:
SERAXIS INC
Seraxis, Inc.
Absstract of: US2021008122A1
0001 The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency.
BOPI
Electronic site
